Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.
研究概览
简要总结
This study will investigate the effect of wearing a small warming patch, the InsuPatch, at the site of the continuous glucose monitor (CGM), also called a sensor. Specifically, we will be looking to see if using the InsuPatch (IP) improves the accuracy of the continuous glucose monitor.
详细描述
Hypotheses:
- Warming of the skin and subcutaneous tissue with the InsuPatch device will improve the accuracy of a CGM as compared to a CGM used alone when both are calibrated with a standard laboratory quality glucose measuring reference standard.
- Warming of the skin and subcutaneous tissue with the InsuPatch device will reduce the lag time of the CGM, as compared to a CGM used alone when both are calibrated with a standard laboratory quality glucose measuring reference standard.
- The combination of the InsuPatch device and a CGM will be well-tolerated and not cause skin irritation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 44 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least 12 months.
- •Age 8 years to less than 45 years old.
- •Subject understands the study protocol and agree to comply with it.
- •Subject is on insulin pump or injection-based basal-bolus therapy
- •Subject comprehends written English.
- •For females, subject not intending to become pregnant during the study.
- •Informed Consent Form signed by the subject
- •No history of altered skin integrity, poor wound healing, adhesive allergy, or previous infection from sensor wear.
- •Hemoglobin A1C ≤10%
排除标准
- •The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol
- •The presence of any of the following diseases:
- •a. Current use of systemic corticosteroids (within the last week) b. Other major illness that in the judgment of the investigator might interfere with the completion of the protocol i. Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
- •Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
- •Current or past use of a continuous glucose sensor is not an exclusion criterion.
- •Active skin condition that would affect sensor placement
- •Use of acetaminophen or Vitamin C supplement within the last 7 days
- •Subject is deemed by the Investigator to be unwilling or unable to follow the protocol;
- •Pregnancy A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study.
研究组 & 干预措施
Sensor alone
Glucose sensor site will not have Insupatch
干预措施: Continuous glucose sensor (Device)
Sensor with Insupatch
Glucose sensor site with Insupatch
干预措施: Insupatch (Device)
结局指标
主要结局
Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.
时间窗: 4 hours after lunch, 8 hours after breakfast
Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use, comparing sensor glucose readings and signal data to serum Yellow Springs Instrument (YSI) glucose measurements, with each subject acting as his or her own control.
次要结局
未报告次要终点